PMID- 26805736
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20191210
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 19
IP  - 1
DP  - 2016 Jan
TI  - [Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations: A 
      Meta-analysis].
PG  - 38-45
LID - 10.3779/j.issn.1009-3419.2016.01.05 [doi]
AB  - BACKGROUND AND OBJECTIVE: The fusion between echinoderm microtubule-associated 
      protein 4 (EML4) and anaplastic lymphatic tumor kinase (ALK) rearrangement is 
      present in approximately 5% of non-small cell lung cancer (NSCLC) patients. It 
      has been regarded as another new target gene after epidermal growth factor 
      receptor (EGFR) and K-ras. Figures showed that the disease control rate could 
      reach up to 80% in NSCLC patients with EML4-ALK fusion gene after treated with 
      ALK inhibitors. Thus, exploring an accurate and rapid detecting method is the key 
      in screening NSCLC patients with EML4-ALK expressions. The aim of this study is 
      to analyze the specificity and sensitivity of IHC in detecting EML4-ALK fusion 
      mutations. To evaluate the accuracy and clinical value of this method, and then 
      provide basis for individual molecular therapy of NSCLC patients. METHODS: Using 
      Pubmed database to search all documents required. The deadline of retrieval was 
      February 25, 2015. Then further screening the articles according to the inclusion 
      and exclusion criteria. Using diagnostic test meta-analysis methods to analyze 
      the sensitivity and specificity of the immunohistochemistry (IHC) method compared 
      with fluorescence in situ hybridization (FISH) method. RESULTS: Eleven 
      literatures were added into the meta analysis, there were 3,234 of total cases. 
      The diagnostic odds ratio (DOR) was 1,135.00 (95%CI: 337.10-3,821.46); the area 
      under curve (AUC) of summary receiver operating characteristic curve (SROC) curve 
      was 0.992,3 (SEAUC=0.003,2), the Q* was 0.964,4 (SEQ*=0.008,7). CONCLUSIONS: 
      Immunohistochemical detection of EML4-ALK fusion gene mutation with specific 
      antibody is feasible. It has high sensitivity and specificity. IHC can be a 
      simple and rapid way in screening EML4-ALK fusion gene mutation and exhibits 
      important clinical values.
FAU - Liu, Chang
AU  - Liu C
AD  - Department of Medical Oncology, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Cai, Lu
AU  - Cai L
AD  - Department of Medical Oncology, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Zhong, Diansheng
AU  - Zhong D
AD  - Department of Medical Oncology, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Tianjin Lung Cancer 
Institute, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
LA  - chi
PT  - Evaluation Study
PT  - Journal Article
PT  - Meta-Analysis
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (EML4-ALK fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
SB  - IM
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics/metabolism/pathology
MH  - *Mutation
MH  - Oncogene Proteins, Fusion/*genetics/metabolism
MH  - Sensitivity and Specificity
PMC - PMC5999806
EDAT- 2016/01/26 06:00
MHDA- 2016/10/07 06:00
PMCR- 2016/01/20
CRDT- 2016/01/26 06:00
PHST- 2016/01/26 06:00 [entrez]
PHST- 2016/01/26 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
PHST- 2016/01/20 00:00 [pmc-release]
AID - zgfazz-19-1-38 [pii]
AID - 10.3779/j.issn.1009-3419.2016.01.05 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2016 Jan;19(1):38-45. doi: 
      10.3779/j.issn.1009-3419.2016.01.05.